Allergan Successfully Completes Tobira Therapeutics Acquisition – Acquisition Adds Global Rights to Highly Differentiated Compounds to Treat Multi-Factorial Elements of NASH – – Cenicriviroc (CVC) First-in-Class Oral CCR2/5 Inhibitor Impacting Inflammation, Fibrosis – – Evogliptin, Oral DPP-4 Inhibitor, in Phase 1 Study as a Potential Treatment for NASH in Combination with CVC Impacting Metabolic Element of Disease – PR Newswire DUBLIN, Nov. 1, 2016 DUBLIN , Nov. 1, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of Tobira Therapeutics, Inc. […]